P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL)

• V. Vorobyev,
• D. H. Yoon,
• M. Kaźmierczak,
• S. Grosicki,
• C. Tarella,
• A. Genua,
• J. S. Kim,
• D. Cohan,
• M. Daugherty,
• I. W. Flinn,
• P. L. Zinzani,
• L. I. Gordon

Affiliations

V. Vorobyev

1 S. P. Botkin City Clinical Hospital, Moscow, Russia

D. H. Yoon

2 University of Ulsan College of Medicine, Seoul, South Korea

M. Kaźmierczak

3 Poznań University of Medical Sciences, Poznań

S. Grosicki

4 Silesian Medical University, Katowice, Poland

C. Tarella

5 IEO Istituto Europeo di Oncologia IRCCS, Milano

A. Genua

6 Università degli studi di Perugia, Terni, Italy

J. S. Kim

7 Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea

D. Cohan

8 Secura Bio, Las Vegas

M. Daugherty

8 Secura Bio, Las Vegas

I. W. Flinn

9 Sarah Cannon Research Institute-Tennessee Oncology, Nashville, United States of America

P. L. Zinzani

10 University of Bologna, Istituto Di Ematologia, Bologna, Italy

L. I. Gordon

11 Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, United States of America